

Catalyst Pharmaceuticals (Tue, Jul 02, 2024)

Buy candidate since Jun 21, 2024

Gain 1.35%

StockInvest.us
Gyneju st. 14, "ROCKIT"
Vilnius, LT-01109
Lithuania



score: **3.21**

#2215/ 54200

Trend: Hold
MV Long: Sell
MV Short: Buy
Pivot: Buy
Volume: Sell
MACD: Buy

Tech commentaries:

The **Catalyst Pharmaceuticals** stock price gained **0.190%** on the last trading day (Tuesday, 2nd Jul 2024), rising from **\$15.77** to **\$15.80**. It has now gained 3 days in a row. It will be exciting to see whether it manages to continue gaining or take a minor break for the next few days. During the last trading day the stock fluctuated **1.41%** from a day low at **\$15.61** to a day high of **\$15.83**. The price has been going up and down for this period, and there has been a 5.33% gain for the last 2 weeks. Volume fell on the last day by **-35 thousand** shares and in total, **738 thousand** shares were bought and sold for approximately **\$11.67 million**. You should take into consideration that falling volume on higher prices causes divergence and may be an early warning about possible changes over the next couple of days.

The stock is moving within a wide and horizontal trend and further movements within this trend can be expected. Given the current horizontal trend, you can expect **Catalyst Pharmaceuticals** stock with a 90% probability to be traded between \$15.24 and \$17.31 at the end of this 3-month period. A break of a horizontal trend is often followed by a large increase in the volume, and stocks seldom manage to go directly from the bottom of a trend up to the top. Stocks turning up in the middle of a horizontal trend are therefore considered to be potential runners.

A buy signal was issued from a pivot bottom point on **Tuesday, June 18, 2024**, and so far it has risen 5.54%. Further rise is indicated until a new top pivot has been found. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Volume fell during the last trading day despite gaining prices. This causes a divergence between volume and price and it may be an early warning. The stock should be watched closely. Some negative signals were issued as well, and these may have some influence on the near short-term development. The **Catalyst Pharmaceuticals** stock holds a buy signal from the short-term Moving Average; at the same time, however, the long-term average holds a general sell signal. Since the longterm average is above the short-term average there is a general sell signal in the stock giving a more negative forecast for the stock. On further gains, the stock will meet resistance from the long-term Moving Average at **\$15.82**. On a fall, the stock will find some support from the short-term average at **\$15.39**. A break-up through the long-term average will give another buy signal, while a fall below the short-term average will add another sell signal and strengthen the general signal.

Catalyst Pharmaceuticals finds support from accumulated volume at \$15.59 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested. On the upside the stock meets some resistance just above today's level from accumulated volume at **\$15.88**, **\$15.94** and **\$16.49**.

This stock is usually traded at a good volume, and with minor daily changes, the risk is considered to be low. During the last day, the stock moved **\$0.220 (1.41%)** between high and low. For the last week, the stock has had daily average volatility of **2.34%**.

Several short-term signals are positive and we conclude that the current level may hold a buying opportunity, as there is a fair chance for **Catalyst Pharmaceuticals** stock to perform well in the short-term period.

Risk: **Low**

Evaluation: **Buy Candidate**

Disclaimer: StockInvest.us is a research service that provides financial data and technical analysis of stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "StockInvest.us". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy.